Clinical Scenarios Emerging from Combined Immunophenotypic, Molecular and Morphologic Analysis of Pancreatic Cancer: The Good, the Bad and the Ugly Scenario

Rahib, 2014, Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States, Cancer Res., 74, 2913, 10.1158/0008-5472.CAN-14-0155

Conroy, 2018, FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer, N. Engl. J. Med., 379, 2395, 10.1056/NEJMoa1809775

Neoptolemos, 2017, Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial, Lancet, 389, 1011, 10.1016/S0140-6736(16)32409-6

Goodman, 2018, Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors, JAMA Oncol., 4, 1237, 10.1001/jamaoncol.2018.1701

Lupinacci, 2018, Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas, Gastroenterology, 154, 1061, 10.1053/j.gastro.2017.11.009

Beatty, 2015, Immune escape mechanisms as a guide for cancer immunotherapy, Clin. Cancer Res., 21, 687, 10.1158/1078-0432.CCR-14-1860

Vanneman, 2012, Combining immunotherapy and targeted therapies in cancer treatment, Nat. Rev. Cancer, 12, 237, 10.1038/nrc3237

Riquelme, 2018, Immunotherapy for Pancreatic Cancer: More Than Just a Gut Feeling, Cancer Discov., 8, 386, 10.1158/2159-8290.CD-18-0123

Mahajan, 2018, Immune Cell and Stromal Signature Associated with Progression-Free Survival of Patients with Resected Pancreatic Ductal Adenocarcinoma, Gastroenterology, 155, 1625, 10.1053/j.gastro.2018.08.009

Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733

Raphael, 2017, Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma, Cancer Cell, 32, 185, 10.1016/j.ccell.2017.07.007

Ostrem, 2013, K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions, Nature, 503, 548, 10.1038/nature12796

Bailey, 2016, Genomic analyses identify molecular subtypes of pancreatic cancer, Nature, 531, 47, 10.1038/nature16965

Qian, 2018, Association of Alterations in Main Driver Genes with Outcomes of Patients with Resected Pancreatic Ductal Adenocarcinoma, JAMA Oncol., 4, e173420, 10.1001/jamaoncol.2017.3420

Collisson, 2011, Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy, Nat. Med., 17, 500, 10.1038/nm.2344

Moffitt, 2015, Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma, Nat. Genet., 47, 1168, 10.1038/ng.3398

Maurer, 2019, Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes, Gut, 68, 1034, 10.1136/gutjnl-2018-317706

Tiriac, 2018, Organoid profiling identifies common responders to chemotherapy in pancreatic cancer, Cancer Discov., 8, 1112, 10.1158/2159-8290.CD-18-0349

Karamitopoulou, 2013, Tumour budding is a strong and independent prognostic factor in pancreatic cancer, Eur. J. Cancer, 49, 1032, 10.1016/j.ejca.2012.10.022

Karamitopoulou, 2018, Tumour budding in pancreatic cancer revisited: Validation of the ITBCC scoring system, Histopathology, 73, 137, 10.1111/his.13508

Kohler, 2015, Detailed analysis of epithelial-mesenchymal transition and tumor budding identifies predictors of long-term survival in pancreatic ductal adenocarcinoma, J. Gastroenterol. Hepatol., 30, 78, 10.1111/jgh.12752

Kalloger, 2015, Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma, Am. J. Surg. Pathol., 4, 472

Lohneis, 2018, Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma, Br. J. Cancer, 118, 1485, 10.1038/s41416-018-0093-y

Zlobec, 2015, Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer, Br. J. Cancer, 112, 1944, 10.1038/bjc.2015.177

Grigore, A.D., Jolly, M.K., Jia, D., Farach-Carson, M.C., and Levine, H. (2016). Tumor budding: The name is EMT. Partial EMT. J. Clin. Med., 5.

Palmans, 2017, Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching, Br. J. Cancer, 116, 58, 10.1038/bjc.2016.382

Zlobec, 2018, Tumour budding in colorectal cancer: Molecular rationale for clinical translation, Nat. Rev. Cancer, 18, 203, 10.1038/nrc.2018.1

Karamitopoulou, 2017, MicroRNA dysregulation in the tumor microenvironment influences the phenotype of pancreatic cancer, Mod. Pathol., 30, 1116, 10.1038/modpathol.2017.35

Knudsen, K.N., Lindebjerg, J., Nielsen, B.S., Hansen, T.F., and Sorensen, F.B. (2017). MicroRNA-200b is downregulated in colon cancer budding cells. PLoS ONE, 12.

Chen, 2014, Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression, Nat. Commun., 5, 5241, 10.1038/ncomms6241

Saitoh, 2018, Involvement of partial EMT in cancer progression, J. Biochem., 164, 257, 10.1093/jb/mvy047

Katoh, 2011, Network of WNT and other regulatory signaling cascades in pluripotent stem cells and cancer stem cells, Curr. Pharm. Biotechnol., 12, 160, 10.2174/138920111794295710

Kalluri, 2009, EMT: When epithelial cells decide to become mesenchymal-like cells, J. Clin. Investig., 119, 1417, 10.1172/JCI39675

Floor, 2011, Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: Distinct, overlapping or same populations, Oncogene, 30, 4609, 10.1038/onc.2011.184

Knudsen, 2017, Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers, Clin. Cancer Res., 23, 4429, 10.1158/1078-0432.CCR-17-0162

Carstens, 2017, Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer, Nat. Commun., 8, 15095, 10.1038/ncomms15095

Martinez-Bosch, N., Vinaixa, J., and Navarro, P. (2018). Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy. Cancers, 10.

Attri, 2018, Evaluation of Macrophage Polarization in Pancreatic Cancer Microenvironment Under Hypoxia, Methods Mol. Biol., 1742, 265, 10.1007/978-1-4939-7665-2_23

Wartenberg, 2018, Integrated genomic and immunophenotypic classification of pancreatic cancer reveals three distinct subtypes with prognostic/predictive significance, Clin. Cancer Res., 24, 4444, 10.1158/1078-0432.CCR-17-3401

Chen, 2013, Molecular mechanisms of T cell co-stimulation and co-inhibition, Nat. Rev. Immunol., 13, 227, 10.1038/nri3405

Hu, 2018, Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations, Clin. Cancer Res., 24, 1326, 10.1158/1078-0432.CCR-17-3099

Castino, 2016, Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma, Oncoimmunology, 5, e1085147, 10.1080/2162402X.2015.1085147

Clear, 2013, Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma, Gastroenterology, 145, 1121, 10.1053/j.gastro.2013.07.025

Balachandran, 2017, Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer, Nature, 551, 512, 10.1038/nature24462

Lee, 2018, Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different, Trends Immunol., 39, 536, 10.1016/j.it.2018.04.005

McGrail, 2018, Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers, Nat. Commun., 9, 1317, 10.1038/s41467-018-03730-x

Connor, 2017, Association of Distinct Mutational Signatures with Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma, JAMA Oncol., 3, 774, 10.1001/jamaoncol.2016.3916

Wartenberg, 2015, Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma, Oncotarget, 6, 4190, 10.18632/oncotarget.2775

Facciabene, 2012, T-regulatory cells: Key players in tumor immune escape and angiogenesis, Cancer Res., 72, 2162, 10.1158/0008-5472.CAN-11-3687

Holmgaard, 2018, Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade, J. Immunother. Cancer, 6, 47, 10.1186/s40425-018-0356-4

Tamborero, 2018, A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations, Clin. Cancer Res., 24, 3717, 10.1158/1078-0432.CCR-17-3509

Danilova, 2019, Programmed cell death ligand-1 (PD-L1) and CD8 expression profiling identify an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival, Cancer Immunol. Res., 7, 886, 10.1158/2326-6066.CIR-18-0822

Roy, 2017, Targeting the hepatocyte growth factor/Met pathway in cancer, Biochem. Soc. Trans., 45, 855, 10.1042/BST20160132

Sahin, 2016, Genomic instability in pancreatic adenocarcinoma: A new step towards precision medicine and novel therapeutic approaches. Expert Rev, Gastroenterol. Hepatol., 10, 893

Vonderheide, 2018, The immune revolution: A case for priming, not checkpoint, Cancer Cell, 33, 563, 10.1016/j.ccell.2018.03.008

Balachandran, 2019, Broadening the impact of immunotherapy to pancreatic cancer: Challenges and opportunities, Gastroenterology, 156, 2056, 10.1053/j.gastro.2018.12.038